Acronyms And Abbreviations |
|
xxi | |
|
|
1 | (4) |
|
Use of Digital Health Technology Applications to Address Pain Points Across the Drug Development Lifecycle |
|
|
2 | (1) |
|
Organization of the Workshop |
|
|
3 | (1) |
|
Organization of the Proceedings |
|
|
4 | (1) |
|
2 Ethical And Regulatory Considerations For Digital Health Technologies |
|
|
5 | (16) |
|
Categories and Uses of Digital Health Technologies |
|
|
6 | (4) |
|
Using Digital Health Technologies to Capture Real-World Evidence |
|
|
10 | (1) |
|
Ethical, Legal, and Social Implications of Digital Health Technologies and Clinical Research |
|
|
11 | (6) |
|
Considerations for the Future |
|
|
17 | (4) |
|
3 Digital Health Technologies For Characterizing Disease |
|
|
21 | (20) |
|
Challenges in Deriving Health Insights from Real-World Sensor Data |
|
|
23 | (4) |
|
Digital Data Collection by the All of Us Research Program |
|
|
27 | (4) |
|
Adoption of Digital Health Technologies |
|
|
31 | (3) |
|
Discovery Through Person-Generated Health Data |
|
|
34 | (4) |
|
|
38 | (3) |
|
4 Digital Health Technologies For Recruitment And Safety |
|
|
41 | (20) |
|
Regulatory Perspective on Drug Development Tools |
|
|
43 | (6) |
|
Engaging the Public in Research Using Mobile Health |
|
|
49 | (3) |
|
Digital Health Technologies and Remote Monitoring in Drug Development |
|
|
52 | (1) |
|
Digital Health Technologies and the COVID-19 Pandemic |
|
|
53 | (3) |
|
Deploying Digital Health Technologies at the Intersection of Clinical Care and Research |
|
|
56 | (4) |
|
|
60 | (1) |
|
5 Digital Health Technologies For Pivotal Trials |
|
|
61 | (14) |
|
Industry Perspective on Digital Health Technologies in Pivotal Trials |
|
|
62 | (3) |
|
Performance Requirements for Digital Health Technologies in Pivotal Trials |
|
|
65 | (4) |
|
Regulatory Perspective on the Use of Digital Health Technologies in Pivotal Trials |
|
|
69 | (3) |
|
|
72 | (3) |
|
6 Digital Health Technologies For Enhancing Real-World Evidence Collection, Patient Centricity, And Post-Market Studies |
|
|
75 | (12) |
|
Digital Health Technologies for Post-Marketing Research and Surveillance |
|
|
76 | (3) |
|
Use of Digital Health Technologies to Empower Patient Participation |
|
|
79 | (5) |
|
Clinician Perspective on Digital Health Technologies for Post-Marketing Research and Surveillance |
|
|
84 | (3) |
|
7 Reflections And Key Takeaways |
|
|
87 | (6) |
|
Challenges Associated with the Use of Digital Health Technologies |
|
|
87 | (1) |
|
Digital Health Technologies to Enable Patient-Centered Drug Development |
|
|
88 | (1) |
|
Standards and Evaluation Frameworks |
|
|
89 | (1) |
|
"Pain Points" Across the Drug Development Process and Solutions Digital Health Technologies Can Provide |
|
|
90 | (9) |
References |
|
93 | (6) |
Appendixes |
|
|
A Workshop Statement Of Task |
|
|
99 | (2) |
|
|
101 | (4) |
|
C Planning Committee Biographical Sketches |
|
|
105 | (8) |
|
D Workshop Speaker Biographical Sketches |
|
|
113 | |